F

Kimberly-Clark (KMB) FY2025 Earnings Quality Report

KMB·FY2025·English

Grade: F — Major Red Flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-12, FY ended December 31, 2025) + Yahoo Finance

Auditor: Deloitte & Touche LLP — Unqualified opinion

One-line verdict: Kimberly-Clark is executing a massive corporate transformation — divesting its International Family Care & Professional business to Suzano for $1.7B, agreeing to acquire Kenvue in a stock-for-stock merger, and running a multi-year "2024 Transformation Initiative" that generated $333M in restructuring charges in FY2025 alone. Meanwhile, cash flow remains robust (CFFO/NI 1.37, FCF/NI 0.81) and the M-Score of -2.54 is clean. But the balance sheet flags are real: cash of $774M covers just 11% of $7.3B in debt, goodwill and intangibles of $1.9B sit at 128% of equity ($1.5B), and the Z-Score of 2.15 places the company in the grey zone. CapEx surged 58% to $1.1B amid declining revenue — a watch item. This is a company restructuring aggressively with a thin equity cushion and a pending mega-merger that will fundamentally reshape its business.

Grade: F — Major Red Flags
MetricResult
Red Flags**2** (financial 2 + management 0; cash covers 11% of debt, goodwill+intangibles 128% of equity)
Watch Items**1** (financial 1 + management 0; CapEx +57.8% vs revenue -2.1%)
Checks Completed**22/23** (financial 17/18 + management 5/5 G1-G5)
Beneish M-Score**-2.54** (clean; threshold is -2.22)
Altman Z-Score**2.15** (grey zone — neither safe nor distressed)
AuditorDeloitte & Touche LLP — Unqualified opinion

The Business: Tissue and Diapers in Transformation

Following the IFP divestiture announcement, Kimberly-Clark now reports two continuing-operations segments: North America (Huggies, Kleenex, Scott, Cottonelle, Depend) and International Personal Care. The IFP Business — tissue brands and professional products outside North America — is reported as discontinued operations. Per the filing: "At the time of closing, Buyer will acquire a 51% interest in the Joint Venture for a purchase price of approximately $1.7 billion."

The Kenvue acquisition is even more transformative: the company agreed to merge with the former J&J consumer health spin-off in a stock-for-stock deal announced November 2, 2025. Acquisition-related costs of $32M were incurred in FY2025.

Profitability: Margin Contraction Under Transformation Costs

Profitability: Margin Contraction Under Transformation Costs
MetricFY2022FY2023FY2024FY2025Trend
Net Sales (cont.)$20.2B$17.1B$16.8B$16.4BRevenue shrinking (partly from divestitures)
Net Income$1.93B$1.76B$2.55B$2.02B-21% YoY
Gross Margin30.8%36.6%37.4%36.0%Contracted -1.4pp
CFFO/NI1.412.011.271.37Stable

The 2024 Transformation Initiative drove $333M in charges in FY2025 ($176M in workforce reductions and $157M in asset-related and other cash exit costs). The IFP discontinued operations generated $400M net income in FY2025 ($3.25B revenue, 28.8% gross margin) — this will disappear after the Suzano joint venture closes.

Revenue decline of 2.1% was driven by competitive pressure. Per the filing: "We've experienced increased competitive pressures from private label manufacturers in the Baby and Child Care and Family Care categories. Increased purchases of private label products could reduce net sales of our higher-margin products."

Cash Flow: Solid Core, Heavy Investment Cycle

Cash Flow: Solid Core, Heavy Investment Cycle
MetricFY2023FY2024FY2025
Operating Cash Flow$3.54B$3.23B$2.78B
Net Income$1.76B$2.55B$2.02B
**CFFO / Net Income****2.01****1.27****1.37**
CapEx$0.77B$0.72B$1.14B
Free Cash Flow$2.78B$2.51B$1.64B

CapEx surged from $721M to $1.14B (+58%), including "incremental spending from the 2024 Transformation Initiative." The company expects CapEx of approximately $1.3B in 2026. Dividends of $1.7B consumed all of FCF. Share repurchases were minimal at $141M (1.1M shares).

Per the filing: "We incurred approximately $100 of incremental tariff-related costs, primarily within our North America segment, related to changes in U.S. trade policy during fiscal 2025."

The 18-Point Screening

Revenue Quality

Revenue Quality
#CheckResultDetail
A1DSO ChangePASSDSO 40 days, +4 days YoY
A2AR vs Revenue GrowthPASSAR +8.1% vs revenue -2.1%
A3Revenue vs CFFOPASSRevenue -2.1%, CFFO -14.1%

Expense Quality

Expense Quality
#CheckResultDetail
B1Inventory vs COGSPASSInventory +1.6% vs COGS +0.1%. Normal
B2CapEx vs RevenueWATCHCapEx +57.8% vs revenue -2.1%
B3SG&A RatioPASSSG&A/Gross Profit = 59.6%. Normal
B4Gross MarginPASS36.0%, -1.4pp. Stable

B2 — CapEx surge reflects transformation-related capital spending. Management disclosed expected CapEx of $1.3B in 2026, suggesting this elevated spending continues. When capital expenditures grow 58% while revenue declines, it raises questions about returns on investment.

Cash Flow Quality

Cash Flow Quality
#CheckResultDetail
C1CFFO vs Net IncomePASSCFFO/NI = 1.37. Strong
C2Free Cash FlowPASSFCF $1.6B, FCF/NI = 0.81
C3Accruals RatioPASS-4.4%. Low accruals
C4Cash vs DebtFAILCash $774M covers only 11% of debt $7.3B

Balance Sheet

Balance Sheet
#CheckResultDetail
D1Goodwill + IntangiblesFAIL$1.9B = 128% of equity
D2LeveragePASSDebt/EBITDA = 2.3x. Healthy
D3Soft Asset GrowthPASSOther assets +11.0% vs revenue -2.1%. Normal
D4Asset ImpairmentN/ANo write-off data

D1 — Equity is razor thin. Total equity of just $1.5B supports $1.9B in goodwill/intangibles, producing a 128% ratio. This is partly structural — Kimberly-Clark has aggressively returned capital to shareholders over decades, shrinking the equity base. But it means any goodwill impairment would push equity negative.

Acquisition Risk

Acquisition Risk
#CheckResultDetail
E1Serial Acquirer FCFPASSFCF after acquisitions positive
E2Goodwill SurgePASSGoodwill+Intangibles +2% YoY. Normal

Manipulation Score

Manipulation Score
#CheckResultDetail
F1Beneish M-ScorePASS-2.54 (threshold: < -2.22)
**G1-G5****Management signals (new)****✅✅✅✅✅**

Management Signals (New G1-G5 Framework)

**Why separate management signals?** Schilit's *Financial Shenanigans* treats abrupt executive, auditor, and director departures as important early-warning signals. 8-K Item 5.02 executive/director changes and auditor-change filings help separate clean financial statements from governance or continuity risk.

Management Signals (New G1-G5 Framework)
#CheckResultDetail
G1CEO changeNo abnormal signal in the last 18 months
G2CFO / key financial officer changeNo abnormal signal in the last 18 months
G3Independent director / audit committee departureNo abnormal signal in the last 18 months
G4Key operating or legal leader departureNo abnormal signal in the last 18 months
G5Auditor changeNo abnormal signal in the last 18 months

Data source: SEC EDGAR 8-K filings filtered for Item 5.02 + management-signals-by-ticker.json

Key Risks from the 10-K

1. Kenvue Merger Integration Risk

The stock-for-stock merger with Kenvue creates a consumer products giant but carries massive integration risk. Per the filing, $32M in acquisition-related costs were already incurred. The deal structure and regulatory approvals remain uncertain.

2. IFP Divestiture Execution

The $1.7B IFP joint venture with Suzano "is expected to close in mid-2026, pending the satisfaction of consultation requirements and customary closing conditions, including obtaining required regulatory approvals." Loss of the IFP business removes $3.25B in revenue and $400M in net income from consolidated results.

3. Private Label Competition

"We've experienced increased competitive pressures from private label manufacturers in the Baby and Child Care and Family Care categories." This is a structural headwind in tissue and diaper categories where brand differentiation is increasingly challenged.

4. Tariff Exposure

"We incurred approximately $100 of incremental tariff-related costs" in FY2025. "In 2026, we expect net input costs, including as a result of tariffs, to be broadly in line with fiscal 2025." Tariff uncertainty adds to the cost environment.

5. Grey Zone Z-Score

The Altman Z-Score of 2.15 places Kimberly-Clark in the grey zone (between 1.8 and 3.0). While not in distress territory, this reflects the thin equity base, significant debt load, and modest profitability relative to total assets.

Summary

Grade: F. Two balance sheet flags driven by a thin equity cushion and heavy debt, compounded by a grey-zone Z-Score and a company in the middle of three simultaneous transformations.

Kimberly-Clark's operating quality is genuinely strong: CFFO/NI of 1.37, negative accruals, clean M-Score, and unqualified audit opinion. The 36.0% gross margin is healthy for household products. The company generates real cash flow from real branded product sales.

But the balance sheet is stretched to its limits. Cash covers 11% of debt. Goodwill exceeds total equity. The Z-Score sits in the grey zone. And the company is simultaneously divesting a $3.25B revenue business, pursuing a mega-merger with Kenvue, and executing a multi-year restructuring with $333M in annual charges. The CapEx surge of 58% against declining revenue is a watch item. Any misstep in this transformation gauntlet could have outsized financial consequences on a balance sheet with virtually no cushion.

**Disclaimer**: This report is based on Kimberly-Clark's FY2025 10-K filed with SEC EDGAR on February 12, 2026. This is NOT investment advice.

Data: SEC EDGAR 10-K + Yahoo Finance

Auditor: Deloitte & Touche LLP (Unqualified opinion)

Fiscal year ended: December 31, 2025

Portfolio monitoring

Monitor KMB and your holdings continuously

The full report is free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and PDF/CSV export workflows.

This report is based on SEC 10-K filings and public financial data. Not investment advice.